Covalon Technology Limited (COV)

[zenvesting]

Good news today, catheter associated urinary tract infections (CAUTIs) are one of the targeted Hospial Acquired Conditions (HAC) for Medicare penalties, so Covalon's Silvercoat Foley catheters are being released into a favorable market.

In October 2014 the Medicare Hospital-Acquired Condition (HAC) Reduction Program began penalizing poor performing hospitals for their rates of three “preventable conditions”, for which Covalon (and it's partners) have already targeted with novel infection control products that are currently on the market. The three equally weighted categories: rates of Central Line-Associated Bloodstream Infections (CLABSIs), rates of Catheter-Associated Urinary Tract Infections (CAUTIs), and other "serious complications" which includes eight types of serious but preventable complications. The criteria will expand in 2015 to include Surgical Site Infections (SSIs) and in 2016 will expand to include incident rates of two antibiotic resistant bacteria: Clostridium difficile and Methicillin-resistant Staphylococcus aureus (MRSA) [1]. Covalon currently has both licensed products and Covalon branded products that are clinically proven to provide superior performance in addressing CLABSIs (IV Clear), CAUTIs (SilverCoat Foley Catheters [Medline Silvertouch Foley Catheters]), and SSIs (SurgiClear).